BioCentury | Feb 2, 2021
Management Tracks

Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem

...a shareholder meeting March 12. Schmidt was director of finance and controlling at InflaRx N.V. (NASDAQ:IFRX).Kadimastem Ltd....
...co-chairperson of its board, and brought on new board members Doron Birger and Ron Mayron.TARGETSTarget BC Staff Kadimastem Vivoryon...
BioCentury | Aug 24, 2015
Clinical News

Kadimastem preclinical data

...In a rat model of ALS, Kadimastem’s hESC-derived astrocyte precursor cells injected into the spinal fluid...
...injected into the spinal fluid significantly improved life expectancy and motor abilities vs. untreated controls. Kadimastem Ltd....
BioCentury | Sep 1, 2014
Company News

Kadimastem, Merck deal

...Kadimastem and Merck’s Merck Serono S.A. division expanded a 2012 deal to use Kadimastem’s stem cell-based...
...expanded deal, Kadimastem will screen compounds from Merck using assays based on stem cell-derived astrocytes. Kadimastem...
...The companies said financial terms are not disclosed. In 2012, the companies partnered to use Kadimastem’s...
BioCentury | Aug 7, 2014
Tools & Techniques

High throughput remyelination

...proprietary compounds that promote remyelination. However, competition could be on the horizon. Earlier this week, Kadimastem Ltd....
...N.Y. Inception 5 Inc. , San Diego, Calif. Inception Sciences Inc. , San Diego, Calif. Kadimastem Ltd....
BioCentury | Nov 11, 2013
Company News

Kadimastem, Merck KGaA deal

...is to establish drug screening assays using stem cell-derived astrocytes (see BioCentury, May 7, 2012). Kadimastem's...
...way to search for potential new drugs. The companies could not be reached for details. Kadimastem Ltd....
BioCentury | Aug 12, 2013
Finance

A disciplined crowd

...NASDAQ:NSTG) 6/25/13 $54.0 -28% 17% -44% KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) 1/31/13 $70.0 -22% 30% -51% Kadimastem Ltd....
BioCentury | Jul 1, 2013
Finance

3Q Financial Markets Preview: Window watching

...TSX-V:ATE) 6/18/13 $2.1 $14.1 $13.7 -3% bluebird bio Inc. (NASDAQ:BLUE) 6/18/13 $116.1 $402.9 $591.8 47% Kadimastem Ltd....
BioCentury | May 7, 2012
Company News

Kadimastem, Merck KGaA deal

...Merck's Merck Serono division partnered with Kadimastem to use the Israeli company's drug-screening technology to discover...
...company's drug-screening technology to discover oral therapies for multiple sclerosis (MS). Under the five-year deal, Kadimastem...
...to search for potential new drugs. Kadimastem will receive financial support. Details were not disclosed. Kadimastem Ltd....
BioCentury | May 1, 2012
Company News

Merck Serono, Kadimastem in MS deal

...Merck Serono partnered with Kadimastem Ltd. (Ness Ziona, Israel) to use the Israeli company's drug-screening technology to...
...Israeli company's drug-screening technology to discover oral therapies for multiple sclerosis. Under the five-year deal, Kadimastem...
...from Merck that stimulate myelin repair. Merck Serono is a unit of Merck KGaA (Xetra:MRK). Kadimastem's...
Items per page:
1 - 9 of 9
BioCentury | Feb 2, 2021
Management Tracks

Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem

...a shareholder meeting March 12. Schmidt was director of finance and controlling at InflaRx N.V. (NASDAQ:IFRX).Kadimastem Ltd....
...co-chairperson of its board, and brought on new board members Doron Birger and Ron Mayron.TARGETSTarget BC Staff Kadimastem Vivoryon...
BioCentury | Aug 24, 2015
Clinical News

Kadimastem preclinical data

...In a rat model of ALS, Kadimastem’s hESC-derived astrocyte precursor cells injected into the spinal fluid...
...injected into the spinal fluid significantly improved life expectancy and motor abilities vs. untreated controls. Kadimastem Ltd....
BioCentury | Sep 1, 2014
Company News

Kadimastem, Merck deal

...Kadimastem and Merck’s Merck Serono S.A. division expanded a 2012 deal to use Kadimastem’s stem cell-based...
...expanded deal, Kadimastem will screen compounds from Merck using assays based on stem cell-derived astrocytes. Kadimastem...
...The companies said financial terms are not disclosed. In 2012, the companies partnered to use Kadimastem’s...
BioCentury | Aug 7, 2014
Tools & Techniques

High throughput remyelination

...proprietary compounds that promote remyelination. However, competition could be on the horizon. Earlier this week, Kadimastem Ltd....
...N.Y. Inception 5 Inc. , San Diego, Calif. Inception Sciences Inc. , San Diego, Calif. Kadimastem Ltd....
BioCentury | Nov 11, 2013
Company News

Kadimastem, Merck KGaA deal

...is to establish drug screening assays using stem cell-derived astrocytes (see BioCentury, May 7, 2012). Kadimastem's...
...way to search for potential new drugs. The companies could not be reached for details. Kadimastem Ltd....
BioCentury | Aug 12, 2013
Finance

A disciplined crowd

...NASDAQ:NSTG) 6/25/13 $54.0 -28% 17% -44% KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) 1/31/13 $70.0 -22% 30% -51% Kadimastem Ltd....
BioCentury | Jul 1, 2013
Finance

3Q Financial Markets Preview: Window watching

...TSX-V:ATE) 6/18/13 $2.1 $14.1 $13.7 -3% bluebird bio Inc. (NASDAQ:BLUE) 6/18/13 $116.1 $402.9 $591.8 47% Kadimastem Ltd....
BioCentury | May 7, 2012
Company News

Kadimastem, Merck KGaA deal

...Merck's Merck Serono division partnered with Kadimastem to use the Israeli company's drug-screening technology to discover...
...company's drug-screening technology to discover oral therapies for multiple sclerosis (MS). Under the five-year deal, Kadimastem...
...to search for potential new drugs. Kadimastem will receive financial support. Details were not disclosed. Kadimastem Ltd....
BioCentury | May 1, 2012
Company News

Merck Serono, Kadimastem in MS deal

...Merck Serono partnered with Kadimastem Ltd. (Ness Ziona, Israel) to use the Israeli company's drug-screening technology to...
...Israeli company's drug-screening technology to discover oral therapies for multiple sclerosis. Under the five-year deal, Kadimastem...
...from Merck that stimulate myelin repair. Merck Serono is a unit of Merck KGaA (Xetra:MRK). Kadimastem's...
Items per page:
1 - 9 of 9